KR910002796A - Piperidine derivatives, preparation method thereof, and pharmaceutical composition comprising the same - Google Patents

Piperidine derivatives, preparation method thereof, and pharmaceutical composition comprising the same Download PDF

Info

Publication number
KR910002796A
KR910002796A KR1019900010077A KR900010077A KR910002796A KR 910002796 A KR910002796 A KR 910002796A KR 1019900010077 A KR1019900010077 A KR 1019900010077A KR 900010077 A KR900010077 A KR 900010077A KR 910002796 A KR910002796 A KR 910002796A
Authority
KR
South Korea
Prior art keywords
lower alkyl
alkyl group
group
optionally substituted
carbon atoms
Prior art date
Application number
KR1019900010077A
Other languages
Korean (ko)
Inventor
야쓰오 이또오
히데오 가또오
에이이찌 고시나까
노부오 오가와
히로유끼 니시노
준 사까구찌
Original Assignee
이또오 겐지
호꾸리꾸 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이또오 겐지, 호꾸리꾸 세이야꾸 가부시끼가이샤 filed Critical 이또오 겐지
Publication of KR910002796A publication Critical patent/KR910002796A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음No content

Description

피페리딘 유도체, 그의 제조방법, 및 그것으로 이루어지는 의약조성물Piperidine derivatives, preparation method thereof, and pharmaceutical composition comprising the same

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (15)

다음 일반식(Ⅰ)로 표시되는 피페리딘유도체 및 식(Ⅰ)의 화합물의 약리학적으로 허용되는 염.Pharmacologically acceptable salts of the piperidine derivative represented by the following general formula (I) and the compound of formula (I). 상기식에서, R은 수소원자 또는 저급알킬기를 나타내며, X는 -CH=CH-, -CH2CH2-, 또는 -CH2O-를 나타내며 ; Y는 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 5개 탄소원자를 갖는 알킬렌기를 나타내거나 또는 Y는 -A-O-B기를 나타내며, 여기서 A와 B는 동일 또는 상이하며 각각 독립적으로 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 3개 탄소원자를 갖는 알킬렌기를 나타낸다.Wherein R represents a hydrogen atom or a lower alkyl group, X represents -CH = CH-, -CH 2 CH 2- , or -CH 2 O-; Y represents an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with a lower alkyl group, or Y represents an -AOB group, wherein A and B are the same or different and each independently be optionally substituted with a lower alkyl group The alkylene group which may have 1-3 carbon atoms is also shown. 4-(5H-디벤조〔a,d〕 시클로헵텐-5-일리덴)-1-피페리딘프로피온산 및 약리학적으로 허용되는 그의 염.4- (5H-dibenzo [a, d] cyclohepten-5-ylidene) -1-piperidinepropionic acid and its pharmacologically acceptable salts. 2-〔4-(5H-디벤조〔a,d〕 시클로헵텐-5-일리덴) 피페리디노〕 에톡시아세트산 및 약리학적으로 허용되는 그의 염.2- [4- (5H-dibenzo [a, d] cyclohepten-5-ylidene) piperidino] ethoxyacetic acid and its pharmacologically acceptable salts. 4-(10,11-디히드로-5H-디벤조〔a,d〕 시클로헵텐-5-일리덴)-1-피페리딘 프로피온산 및 약리학적으로 허용되는 그의 염.4- (10,11-Dihydro-5H-dibenzo [a, d] cyclohepten-5-ylidene) -1-piperidine propionic acid and pharmacologically acceptable salts thereof. 4-(디벤즈〔b,e〕 옥세핀-11(6H)-일리덴)-피페리딘 아세트산 및 약리학적으로 허용되는 그의 염.4- (Dibenz [b, e] oxepin-11 (6H) -ylidene) -piperidine acetic acid and its pharmacologically acceptable salts. 2-(4-(디벤즈〔b,e〕 옥세핀-11(6H)-일리덴)피페리디노〕 에톡시아세트산 및 약리학적으로 허용되는 그의 염.2- (4- (dibenz [b, e] oxepin-11 (6H) -ylidene) piperidino] ethoxyacetic acid and its pharmacologically acceptable salts. 다음 일반식(Ⅰ)로 표시되는 피페리딘유도체 및 식(Ⅰ)의 화합물의 약리학적으로 허용되는 염의 제조방법에 있어서,In the method for preparing a pharmacologically acceptable salt of the piperidine derivative represented by the following general formula (I) and the compound of formula (I), (상기식에서 R은 수소 또는 저급알킬기를 나타내며, X는 -CH=CH-, -CH2CH2-, 또는 -CH2O-를 나타내며 ; Y는 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 5개 탄소원자를 갖는 알킬렌기를 나타내거나 또는 Y는 -A-O-B기를 나타내며, 여기서, A와 B는 동일 또는 상이하며 각각 독립적으로 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 3개 탄소원자를 갖는 알킬렌기를 나타낸다.(Wherein R represents hydrogen or lower alkyl group, X represents -CH = CH-, -CH 2 CH 2- , or -CH 2 O-; Y is 1 to 5 which may be optionally substituted with lower alkyl group) Represents an alkylene group having 3 carbon atoms or Y represents an -AOB group, wherein A and B each represent an alkylene group having 1 to 3 carbon atoms which may be the same or different and may be optionally substituted independently with a lower alkyl group. . 다음 일반식(Ⅱ)General formula (Ⅱ) (여기서 X는 상기한 바와 같다)로 표시되는 피페리딘유도체를 Z-Y-COOR(Ⅲa) 또는 CH2=CHCOOR(Ⅲb)(여기서 R은 Y는 상기 정의한 것과 같고, Z는 할로겐원자를 나타낸다)로 표시되는 화합물과, 반응시키는 단계와, 이어서 필요하다면 산 또는 염기를 사용하여 용매중에서 가수분해시키는 단계로 이루어지는 것을 특징으로 하는 제조방법.Wherein the piperidine derivative represented by X is as described above as ZY-COOR (IIIa) or CH 2 = CHCOOR (IIIb), where R is as defined above and Z represents a halogen atom A process comprising the step of reacting with a compound represented, followed by hydrolysis in a solvent using an acid or a base if necessary. 제7항에 있어서, 상기 반응시키는 단계는 용매의 존재하에 수행되는 것을 특징으로 하는 제조방법.The method of claim 7, wherein the step of reacting is carried out in the presence of a solvent. 제7항에 있어서, 상기 반응시키는 단계는 용매의 부재하에 수행되는 것을 특징으로 하는 제조방법.8. A process according to claim 7, wherein said step of reacting is carried out in the absence of a solvent. 제7항에 있어서, 상기 반응시키는 단계는 탈수소할로겐화제로서 염기의 존재하에 수행되는 것을 특징으로 하는 방법.8. The method of claim 7, wherein said step of reacting is carried out in the presence of a base as a dehydrohalogenating agent. 제7항에 있어서, 상기 반응시키는 단계는 탈수소할로겐화제로서 염기의 부재하에 수행되는 것을 특징으로 하는 방법.8. The method of claim 7, wherein said reacting is carried out in the absence of a base as a dehydrohalogenating agent. 다음 일반식(Ⅰ)로 표시되는 피페리딘 유도체 및 식(Ⅰ)의 화합물의 약리학적으로 허용되는 염 유효량으로 이루어지는 항히스타민 및 항알레르기 약제.An antihistamine and an antiallergic agent comprising a piperidine derivative represented by the following general formula (I) and an effective pharmacologically acceptable salt amount of the compound of formula (I). 상기식에서 R은 수소원자 또는 저급알킬기를 나타내며, X는 -CH=CH-, -CH2CH2-, 또는 -CH2O-를 나타내며 ; Y는 저급알킬로 임의적으로 치환될 수도 있는 1 내지 5개 탄소원자를 갖는 알킬렌기를 나타내거나 또는 Y는 -A-O-B기를 나타내며, 여기서 A와B는 동일 또는 상이하며 각각 독립적으로 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 3개 탄소원자를 갖는 알킬렌기를 나타낸다.R represents a hydrogen atom or a lower alkyl group, X represents -CH = CH-, -CH 2 CH 2- , or -CH 2 O-; Y represents an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with lower alkyl, or Y represents an -AOB group, wherein A and B are the same or different and each independently be optionally substituted with a lower alkyl group The alkylene group which may have 1-3 carbon atoms is also shown. 다음 일반식(Ⅰ)로 표시되는 피페리딘유도체 및 식(Ⅰ)의 화합물의 약리학적으로 허용되는 염 유효량으로 이루어지는 알레르기질환의 치료용 의약조성물.A pharmaceutical composition for the treatment of allergic diseases, comprising a piperidine derivative represented by the following general formula (I) and an effective pharmacologically acceptable salt amount of the compound of formula (I). 상기식에서 R은 수소원자 또는 저급알킬기를 나타내며, X는 -CH=CH-, -CH2CH2-, 또는 -CH2O-를 나타내며 ; Y는 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 5개 탄소원자를 갖는 알킬렌기를 나타내거나 또는 Y는 -A-O-B기를 나타내며, 여기서 A와B는 동일 또는 상이하며 각각 독립적으로 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 3개 탄소원자를 갖는 알킬렌기를 나타낸다.R represents a hydrogen atom or a lower alkyl group, X represents -CH = CH-, -CH 2 CH 2- , or -CH 2 O-; Y represents an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with a lower alkyl group, or Y represents an -AOB group, where A and B are the same or different and each independently be optionally substituted with a lower alkyl group The alkylene group which may have 1-3 carbon atoms is also shown. (a) 다음 일반식(Ⅰ)로 표시되는 피페리딘유도체, (b) 식(Ⅰ)의 화합물의 약리학적으로 허용되는 염, (c) 식(Ⅰ)의 화합물로 이루어지는 항히스타민 및 항알레르기 약제, 또는 (d) 식(Ⅰ)의 화합물로 이루어지는 의약조성물로 본질적으로 구성되는 군으로부터 선택된 물질 유효량을 포유동물에 투여하는 단계로 이루어지는 알레르기 질환의 치료방법.(a) an antihistamine and an antiallergic agent comprising a piperidine derivative represented by the following general formula (I), (b) a pharmacologically acceptable salt of the compound of formula (I), (c) a compound of formula (I) Or (d) administering to a mammal an effective amount of a substance selected from the group consisting essentially of a pharmaceutical composition comprising the compound of formula (I). 상기식에서 R은 수소원자 또는 저급알킬기를 나타내며, X는 -CH=CH-, -CH2CH2-, 또는 -CH2O-를 나타내며 ; Y는 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 5개 탄소원자를 갖는 알킬렌기를 나타내거나 또는 Y는 -A-O-B기를 나타내며, 여기서 A와 B는 동일 또는 상이하며 각각 독립적으로 저급알킬기로 임의적으로 치환될 수도 있는 1 내지 3개 탄소원자를 갖는 알킬렌기를 나타낸다.R represents a hydrogen atom or a lower alkyl group, X represents -CH = CH-, -CH 2 CH 2- , or -CH 2 O-; Y represents an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with a lower alkyl group, or Y represents an -AOB group, wherein A and B are the same or different and each independently be optionally substituted with a lower alkyl group The alkylene group which may have 1-3 carbon atoms is also shown. 제14항에 있어서, 상기 투여단계는 사람에게 수행되는 것을 특징으로 하는 치료방법.The method of claim 14, wherein said administering step is performed on a human. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019900010077A 1989-07-04 1990-07-04 Piperidine derivatives, preparation method thereof, and pharmaceutical composition comprising the same KR910002796A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP1-171090 1989-07-04
JP17109089 1989-07-04
JP2092194A JPH03128354A (en) 1989-07-04 1990-04-09 Piperidine derivative
JP2-92194 1990-04-09

Publications (1)

Publication Number Publication Date
KR910002796A true KR910002796A (en) 1991-02-26

Family

ID=15916808

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900010077A KR910002796A (en) 1989-07-04 1990-07-04 Piperidine derivatives, preparation method thereof, and pharmaceutical composition comprising the same

Country Status (5)

Country Link
JP (1) JPH03128354A (en)
KR (1) KR910002796A (en)
CA (1) CA2018942A1 (en)
PT (1) PT94599A (en)
ZA (1) ZA904665B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2914324B2 (en) * 1995-10-23 1999-06-28 味の素株式会社 Crystal of piperidine derivative, intermediate for producing the same, and production method

Also Published As

Publication number Publication date
ZA904665B (en) 1991-04-24
PT94599A (en) 1991-03-20
CA2018942A1 (en) 1991-01-04
JPH03128354A (en) 1991-05-31

Similar Documents

Publication Publication Date Title
FI904424A0 (en) Analogous method for the preparation of a biphenylimidazopyridine derivative useful as a medicament
KR930701402A (en) N-hydrocarbyl-4- substituted piperidines, methods for their preparation and their use as calcium blockers
KR960034205A (en) Piperidine derivatives, their preparation and their therapeutic use
NO942309L (en) 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivatives
US5153207A (en) Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
US5095022A (en) Piperidine derivatives and pharmaceutical compositions comprising the same
KR880011154A (en) Benzoxazine Derivatives And Methods For Preparing The Same
KR910002796A (en) Piperidine derivatives, preparation method thereof, and pharmaceutical composition comprising the same
NO178025C (en) Analogous Process for Preparation of Therapeutically Active (Benzhydryloxyethylpiperidyl) Aliphatic Acid Derivatives
KR920002517A (en) Benzhydryl derivatives having a calmodulin inhibitory property and preparation method thereof
US4366162A (en) Aryl ethers of N-alkyl-piperidines and acid addition salts thereof
KR930006003A (en) Imidazolylmethyl-pyridine compounds
KR960017669A (en) Amphoteric Tricyclic Compound
KR920005720A (en) Method for preparing pyridine derivative thereof and pharmaceutical composition thereof
EP0347902A3 (en) Pyrrolecarboxylic acid derivatives
KR870005985A (en) Guanidinobenzo ester derivative and preparation method thereof
ATE120743T1 (en) PYRIDOINDOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
KR950000691A (en) Piperidine and Piperazine
US5077301A (en) 4-(hydroxydiphenylmethyl)-1-piperidylphenylalkane derivatives as antihistamines and methods of treatment of an allergic response
US4320128A (en) Chromanone derivatives and compositions containing them
KR920002594A (en) 5-isothiazolamine derivative
DE3884518D1 (en) NAPHTHOTHIAZEPINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
KR900006287A (en) Side chain alkyl esters of 2- [4- (2-piperidino-ethoxy) -benzoyl] -benzoic acid, methods for their preparation and their use as antispasmodics
RU95120590A (en) NEW ERYTHROMYCIN DERIVATIVES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND INTERMEDIATE SYNTHESIS COMPOUNDS
KR870006051A (en) Theophylline derivatives, preparation method and use thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application